Annexon (ANNX) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed Annexon (ANNX) over the past year, gaining 166.3% versus a gain of 27.0%. Over five years, OABI leads with a -53.3% price change compared with -81.8% for ANNX. Annexon is the larger company by market cap ($758.3 million vs $677.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | OABI |
|---|---|---|
| Share price | $4.00 | $4.66 |
| Market cap | $758.32M | $677.52M |
| 1-day change | -0.25% | +2.19% |
| YTD return | -20.32% | +151.89% |
| 1-year return | +26.98% | +166.29% |
| 5-year return | -81.82% | -53.26% |
| EPS (TTM) | $-1.13 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $5.43 |
| 52-week low | $2.54 | $1.30 |
| Distance from 52-week high | -44.29% | -14.18% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +285.75% | +78.76% |
| Average volume | 3.11M | 1.47M |
| Shares outstanding | 189.58M | 145.39M |
| Employees | 92 | 89 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed ANNX by 139.3 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Healthcare · Biotechnology · 92 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Healthcare · Biotechnology · 89 employees
ANNX vs OABI FAQ
Which is bigger, Annexon or OmniAb?
Annexon (ANNX) is larger, with a market capitalization of $758.32M compared with $677.52M for OmniAb (OABI).
Which stock has performed better over the past year, ANNX or OABI?
OABI returned +166.29% over the past 12 months, compared with +26.98% for ANNX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.